HCMOGT-1 is a Novel Fusion Partner to PDGFRB in Juvenile Myelomonocytic Leukemia with T(5;17)(q33;p11.2)
Overview
Authors
Affiliations
PDGFRB, a transmembrane tyrosine kinase receptor for platelet-derived growth factor, is constitutively activated by gene fusion with different partners in myeloproliferative/myelodysplastic disorders with peculiar clinical characteristics. Six alternative partner genes have been described thus far. In this study, we report the molecular cloning of a novel translocation t(5;17)(q33;p11.2) in a case of juvenile myelomonocytic leukemia. The novel partner gene was identified as HCMOGT-1 using 5'-rapid amplification of cDNA ends; fluorescence in situ hybridization and reverse transcriptase-PCR analyses confirmed that the translocation resulted in PDGFRB/HCMOGT-1 fusion. We show that the breakpoint of PDGFRB occurred at the same site of all previously reported PDGFRB translocations.
LNK/ as a novel driver in juvenile myelomonocytic leukemia.
Wintering A, Hecht A, Meyer J, Wong E, Hubner J, Abelson S Haematologica. 2023; 109(8):2533-2541.
PMID: 38152053 PMC: 11290546. DOI: 10.3324/haematol.2023.283776.
Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia.
Finana C, Gomez-Molina N, Alonso-Moreno S, Belver L Cancers (Basel). 2022; 14(5).
PMID: 35267643 PMC: 8909150. DOI: 10.3390/cancers14051335.
Borogovac A, Sahu K, Vishwanathan G, Miron P, cerny J Cancer Manag Res. 2021; 13:8841-8847.
PMID: 34858057 PMC: 8629764. DOI: 10.2147/CMAR.S324718.
Wintering A, Dvorak C, Stieglitz E, Loh M Blood Adv. 2021; 5(22):4783-4793.
PMID: 34525182 PMC: 8759142. DOI: 10.1182/bloodadvances.2021005117.
Current Treatment of Juvenile Myelomonocytic Leukemia.
Mayerhofer C, Niemeyer C, Flotho C J Clin Med. 2021; 10(14).
PMID: 34300250 PMC: 8305558. DOI: 10.3390/jcm10143084.